Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

Case Study: Successful Medical Device Development with EvoLV’s Consulting

Dec 15, 2025

Introduction to EvoLV’s Consulting

In the competitive world of medical device development, bringing a product from concept to market requires not only innovation but also strategic guidance. EvoLV’s Consulting has proven to be a leader in this sector, offering tailored solutions that help companies navigate complex regulatory landscapes and accelerate time-to-market.

In this case study, we explore how EvoLV’s Consulting contributed to the successful development of a cutting-edge medical device, highlighting the key strategies and outcomes that underscored this achievement.

medical device development

Understanding Client Needs

The client, a promising startup, approached EvoLV’s Consulting with an innovative idea for a wearable health monitoring device. The challenge was to transform this idea into a market-ready product while ensuring compliance with stringent industry standards.

EvoLV’s Consulting began by conducting a comprehensive needs assessment, identifying potential roadblocks and aligning the project’s objectives with the client's vision. This initial stage was crucial in establishing clear goals and expectations.

Strategic Planning and Development

Once the foundational goals were set, EvoLV’s Consulting crafted a strategic roadmap. This plan involved:

  • Detailed product design and prototyping.
  • Rigorous testing and validation processes.
  • Regulatory compliance and documentation.

Each step was meticulously executed, ensuring that the device met all necessary safety and performance standards. EvoLV’s expertise in navigating regulatory requirements proved invaluable, significantly reducing the time usually required to obtain approvals.

strategic planning

Collaboration and Innovation

Collaboration was at the heart of this project. EvoLV’s Consulting worked closely with the client’s team, fostering an environment of open communication and continuous innovation. This partnership enabled rapid iteration and refinement of the device, integrating the latest technological advancements to enhance functionality and user experience.

The consulting team also facilitated workshops and brainstorming sessions, encouraging creative problem-solving and ensuring that the final product exceeded market expectations.

Outcome and Impact

The result was a successful product launch, with the device quickly gaining traction in the market. Thanks to EvoLV’s strategic guidance, the client not only met their launch timeline but also positioned themselves as a leader in the wearable health tech industry.

successful product launch

Moreover, the collaboration with EvoLV’s Consulting resulted in a robust framework for future product developments, setting the stage for sustained innovation and growth.

This case study illustrates the pivotal role that strategic consulting plays in medical device development. With EvoLV’s expertise, companies can confidently navigate the complexities of the industry and achieve remarkable success.

Conclusion

In conclusion, EvoLV’s Consulting demonstrated how a strategic approach to medical device development can lead to successful outcomes. By understanding client needs, crafting detailed plans, fostering collaboration, and ensuring compliance, EvoLV enables companies to transform innovative ideas into market-leading products.

As the medical device industry continues to evolve, partnerships with experienced consultants like EvoLV will be instrumental in driving innovation and delivering impactful solutions to the market.